anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a traditional Chinese medicine pill for benefiting stomach, which is prepared from the following components in parts by weight: the traditional Chinese medicine composition is prepared from 13 traditional Chinese medicines including adenophora stricta, dwarf lilyturf tuber, dendrobium, dark plum fruit, dandelion, processed pinellia tuber, bamboo root, dried orange peel, salvia miltiorrhiza, white paeony root, bitter orange, raw malt and coptis chinensis. 1. Has no influence or little influence on normal physiological functions and no toxic or side effect. 2. The effect is nonspecific and broad-spectrum. 3. Has the normal physiological functions of regulating yin and yang, nourishing yin and promoting the production of body fluid, nourishing yin and clearing stomach, benefiting stomach and moistening dryness, and has the treatment effects on red and dry lips, bitter taste in mouth, halitosis, fantod and desire for drinking and the like. 4. Can improve symptoms and signs of chronic stomach and yin deficiency stomach heat and nourish stomach yin.
PURPOSE:To obtain the titled preparation having suppressed tendency of generation of insoluble foreign material with time and useful as an antibacterial agent, by filling a solution of a specific acid addition salt of a pyridonecarboxylic acid in a container having silicone-coated inner surface. CONSTITUTION:A solution of an acid addition salt of a pyridonecarboxylic acid having antibacterial activity, capable of forming an acid addition salt and expressed by formula [R is (lower alkyl-substituted) 1-piperazinyl, amino or 1-pyrrolidinyl, etc., substituted with lower alkylamino, etc.; A is N or C-X (X is H or halogen); B is N, C-X or together with R1 form a 5-6-membered ring; Y is H, amino, etc.; R1 is alkyl, cycloalkyl, etc.] is filled in a container having silicone-coated inner surface to obtain the objective pyridonecarboxylic acid preparation. The compound of formula is e.g. a pyrido[2,3-d]pyrimidine derivative wherein both A and B are N or a 1,8-naphthyridine derivative wherein A is C-X and B is N.
OBJECTIVES: The HEART score is a clinical decision tool that stratifies patients into categories of low, moderate, and high-risk of major adverse cardiac events in the emergency department (ED) but cannot identify underlying cardiovascular disease in patients without prior history. The presence of atherosclerosis can easily be detected at the bedside using carotid ultrasound. Plaque quantification is well established, and plaque composition can be assessed using ultrasound grayscale pixel distribution analysis. This study aimed to determine whether carotid plaque burden and/or composition correlated with risk of events and could improve the sensitivity of the HEART score in risk stratifying ED patients with chest pain.
METHODS: The HEART score was calculated based on history, electrocardiogram, age, risk factors, and initial troponin in patients presenting to the ED with chest pain (n = 321). Focused carotid ultrasound was performed, and maximum plaque height and total plaque area were used to determine plaque burden (quantity). Plaque composition (% blood, fat, muscle, fibrous, calcium-like tissue) was assessed by pixel distribution analysis.
RESULTS: Carotid plaque height and area increased with HEART score (p < 0.0001). Carotid plaque % fibrous and % calcium also increased with HEART score. The HEART score had a higher area under the curve (AUC = 0.84) in predicting 30-day events compared to the plaque variables alone (AUCs < 0.70). Integrating plaque quantity into the HEART score slightly increased test sensitivity (62-69%) for 30-day events and reclassified 11 moderate-risk participants to high-risk (score 7-10).
CONCLUSION: Plaque burden with advanced composition features (fibrous and calcium) was associated with increased HEART score. Integrating plaque assessment into the HEART score identified subclinical atherosclerosis in moderate-risk patients.
The present invention relates to analogues of anti-thrombin polypeptides and to a process for their preparation. The analogues have been obtained by a C-terminal modification of anti-thrombin polypeptides isolated from the leech Hirudinaria manillensis and are characterized by an improved biological activity in comparison to the polypeptides from which they are derived. The analogues of the invention may be prepared by: 1) isolating the anti-thrombin polypeptide from the tissue or secretions of the leech Hirudinaria manillensis and 2) subsequently modifying the C-terminal end of such polypeptide. Alternatively, the analogues may also be synthetized by recombinant DNA methods. According to this latter aspect, the invention provides DNA sequences, expression vectors and host cell lines for the recombinant preparation of the analogues. The analogues of the invention find a useful application in the treatment of venous thrombosis, vascular shunt occlusion and thrombin-induced disseminated intravascular coagulation.
BACKGROUND: Spinocerebellar ataxia with axonal neuropathy type 1 (OMIM: 607250) is an extremely rare autosomal recessive disorder caused by a mutation in the tyrosyl-DNA phosphodiesterase 1 (TDP1) gene. Only a single missense variant (p.His493Arg) in this gene has been reported. This variant was found in three Arab families with a possible common founder effect.
METHODS AND RESULTS: We report a female patient born to a consanguineous Pakistani family segregating autosomal recessive spinocerebellar ataxia with axonal neuropathy type 1. The patient presents additional clinical features distinct from previously reported Arab families including congenital onset of the disease. We performed whole exome sequencing with the patient's DNA and identified a novel missense variant (NC_000014.9:g.89991982C > T; p.His478Tyr) in exon 13 of the TDP1 gene. Sanger sequencing was performed to verify the autosomal recessive segregation of the p.His478Tyr variant in the family.
CONCLUSION: The current study expands both the clinical and mutation spectrum of the TDP1 associated spinocerebellar ataxia with axonal neuropathy type 1 and increases the body of evidence that supports the pathogenic role of TDP1 in cerebellar ataxias with peripheral neuropathy.
Although administration of ZDV to mother-infant pairs has dramatically reduced perinatal HIV infection, the goal is to reduce it further to less than 2%. In order to achieve this, combination strategies need to be developed for 2 purposes: 1) to reduce the perinatal transmission rate to goal levels; and 2) to provide other combination therapies for HIV-infected mothers whose virus has become resistant to ZDV, who have a very high viral load, or who have previously transmitted HIV while on ZDV. This study adds 3TC (another reverse transcriptase inhibitor) and SQV (a protease inhibitor \[PI\]) \[AS PER AMENDMENT 08/15/00: with low-dose RTV (another PI)\] to the mother's ZDV regimen.

During the antepartum period, mothers receive SQV with \[AS PER AMENDMENT 08/15/00: low-dose RTV plus\] ZDV and 3TC. At onset of active labor, mothers receive loading doses of each of the study drugs, then receive study drugs for 12 weeks postpartum on the same schedule as during the antenatal period. Within 12 hours of delivery, infants begin receiving 3TC and ZDV and continue until 6 weeks of age. Mothers are followed until 12 weeks postpartum and babies are followed until 6 months of age. \[AS PER AMENDMENT 02/09/99: For maternal dosing, 1 Combivir tablet (containing 3TC and ZDV) may be administered in place of the individual agents 3TC and ZDV. Patients who prematurely discontinue study treatment should continue to be followed for the duration of the study.\]
Patients undergo 3D-CRT or IMRT on days 1-5 for 5-7 weeks. Patients also receive procarbazine hydrochloride PO on days 8-21, lomustine PO on day 1 and vincristine sulfate IV on days 8 and 29 of courses 3-8. Treatment repeats every 6-7 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
PROBLEM TO BE SOLVED: To use an HMG-coenzyme A reductase inhibitor as an antiaging agent in a cosmetic and/or dermatological composition. SOLUTION: The objective composition contains 0.00001-2 wt.% of an HMG- coenzyme A reductase selected from mevastatin, lovastatin, pravastatin, simvastatin, flavastatin, dalvastatin and their mixture, as an antiaging agent. The composition is further compounded with 0.1-5 wt.% of activation agents (e.g. α-hydroxy acid and glycol) and adjuvants, etc. It is effective for treating the wrinkles, fine lines, marks, abnormal discoloration, cicatrices, ichthyosis, acne, etc., of the skin and recovering the luster of the skin. The antiaging agent produced by this process has the effect comparable to that of conventional keratolytic agent such as α-hydroxy acid and retinoid, giving weak stimulation to the skin and free from the problem of intolerance.
The present invention relates to a method for discontinuing a treatment with a TKI by determining the number and/or frequency of innate CD8(+) T-cells in subject and concluding that the treatment with a TKI should be discontinued when the number and/or frequency of innate CD8 T-cells is higher than the predetermined reference value. Inventors evaluated whether innate CD8(+) T-cells are an early target of CML therapy success. Among peripheral blood effector CD8(+) T-cells, inventors shown that both number nd/or frequency and functional signatures of innate CD8(+) T-cells are enhanced as early as 3 months of therapy. Strikingly, they observe that patients with high innate CD8(+) T-cell number and/or frequency at 3 months and/or diagnosis achieve a DMR earlier than patients with low innate CD8(+) T-cell number. Furthermore, a higher number and/or frequency of high innate CD8(+) T-cell patients achieved a stable DMR for over 2 years. They have also observed that the success of TKI therapy cessation is associated with higher proportion of innate CD8 T-cells expressing perforin. Collectively, these findings highlight innate CD8(+) T-cells as a potential marker for both CML therapy success and successful long-term treatment-free remission (TFR), and thus therapy discontinuation eligibility.
Lymphedema from various etiologies (i.e. infection, cancer, surgery, and rheumatoid arthritis) remains a major health concern. Efforts to develop effective treatments for this condition have been limited by the absence of quantitative outcome measures for lymphatic function. Published articles have supported the fact that human lymphatic contractions can be readily visualized after intradermal administration of micrograms of Indocyanine Green using laser-induced fluorescence. The use of lasers imposes a risk of eye injury that requires protective eyewear. To address the risk of laser-induced injury, an imaging system was developed by Drs. Ronald Wood and Jay Reeder in a collaborative effort at the University of Rochester. In place of a laser, this system utilizes a tungsten-halogen lamp fitted with a bandpass filter and a multispectral camera for real-time image acquisition and display. This phase 1 study will examine the validity and reliability of this instrument to measure lymphatic transport, contractions, and pressure in the arms of healthy research subjects and establish baseline parameters for subsequent evaluation of rheumatoid arthritis patients in later studies. Indocyanine Green is a dye that has been used clinically for over 50 years to evaluate hepatic clearance, cardiovascular function testing, and retinal angiography. Indocyanine Green has typically been administered intravenously at concentrations of 2.5 mg/ml at total doses of 25 mg in adults. In this study, intradermal administration of micrograms of Indocyanine Green will be used to establish useful dose ranges and concentrations. The dosage regimen for this study is based on prior demonstrations in published articles of successful noninvasive imaging of lymphatic contractions after intradermal administration of microgram amounts of Indocyanine Green.
A measurement device  20  acquires biological information of a user and transmits the biological information to a terminal device  30 - 1 . The terminal device transmits the biological information to a server  40 . The server  40  calculates physical power and mental power using the biological information of the user. Furthermore, the server  40  generates activity support information for the user on the basis of the physical power and the mental power that are calculated, and transmits the activity support information to the terminal device  30 - 1 . The terminal device  30 - 1  notifies the user of the activity support information supplied from the server  40  by an image or a sound. Therefore, the user can determine a type of activity and a time length that are possible with his/her remaining powers, and can perform an activity according to his/her remaining powers.
Composition for the mouth and throat contains isotonic natural saline solution, a synthetic or natural antimicrobial agent, a natural flavouring, together with a non-toxic excipient or vehicle suitable for local administration.  Saline solution is preferably obtained by diluting sea water to obtain isotonicity either before or after its filtration and optional partial deionisation or partial ion-exchange. Antimicrobial agent may be e.g. phenolic or dihydro aromatic derivative (e.g. guaiacol); biguanides (e.g. chlorhexidine); or boric acid salts. Flavouring is preferably plant essence from e.g. (wild) thyme, oregano, coriander etc. Composition may further contain quat. ammonium antibacterials (e.g. benzalkonium chloride.)
For this study, sophomores who are enrolled in health at Jesuit High School, (n = 320 students) will be invited to participate in a research study, conducted during health class, comparing mindfulness to a wellness or waitlist control. The students will be randomized by classroom, to either wellness or mindfulness or waitlist, with approximately 3-4 classes per intervention or control. Initially, six classes or sections of health will be randomized to one of the two active interventions, with the remaining classes/sections of health on the waitlist. Both of the intervention groups will meet weekly, during one of the regularly scheduled health classes, and have daily assignments. The students in the waitlisted classrooms will receive an intervention at the start of the next term. At the end of the study, students will have access to the materials from the other group, if desired.
Environmental Music Therapy (EMT) is a music therapy technique that uses live music to modulate the potentially stressful effects of the environment towards an atmosphere that provides a sense of comfort and security. The instruments used will be an acoustic guitar (Yamaha C-40), an ocean drum (a drum with a double skin on which small metal balls roll imitating the sound of the waves) and a Samafon (an instrument consisting of aluminum tubes of different sizes that are struck with a soft mallet producing long-lasting single or combined tones). The music will consist of improvised music at a slow to moderate tempo, using free-flowing melodies, and simple chord progressions, focusing on creating moments of tension and resolution. The music therapist will also use his/her voice, but without any lyrics or words. After approximately 20 minutes, the music therapist will gradually decrease the volume until the music stops.
According to the present invention, the analgesic and antispasmodic activities of the aqueous extract of  Nigella sativa  (at doses of 1 and 2 mg / kg IP) were studied. Analgesic activity was assessed by the sensitivity test (for central action), induced by acetic acid, and by the writhing test (for peripheral action) in mice. Antispasmodic activity was assessed by the isometric transducer in rabbits. The aqueous extract at a test dose of 1 and 2 mg / kg considerably lengthens (P < 0.05) the latency time of the thermally induced pain reaction in mice compared with morphine (M) at a dose of 0.1 mg / kg, and significantly (P < 0.001) inhibits the writhing induced by acetic acid. The extract has been proven to have significant analgesic activity compared with acetylsalicylic acid (ASA) at a dose of 150 mg / kg. In addition, the aqueous extract causes dose-dependent relaxation in rabbit intestines with an IC 50  of the order of 64.7 ± 1.2 pg / ml and a very significant antispasmodic effect compared with trimebutine as a positive control (IC 50  = 49.6 ± 1.1 pg / ml). The conclusion is that the aqueous extract of NS has antinociceptive and antispasmodic activity.
INTRODUCTION: Despite advancements in the treatment of benign prostatic hyperplasia (BPH), the mechanisms underlying BPH development and progression remain elusive and lacks a one-size-fits-all therapeutic solution. Prostatic inflammation contributes to BPH and lower urinary tract symptoms (LUTS), but the initial trigger remains unknown. Current research suggests dysbiosis of the urinary microbiome as a potential culprit. This systematic review explores the emerging field of the male urinary and prostatic microbiome and its relationship with BPH/LUTS.
METHODS: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed. A systematic search in the Pubmed and Scopus databases was performed using specific terms. Inclusion criteria considered male non-neurogenic patients with LUTS due to BPH with analyses of urinary microbiome, concerning evaluation of English-language publications with relevance.
RESULTS: Among seven articles involving 542 patients, there was an association between male LUTS/BPH and the urinary microbiome. Findings indicate a correlation between urinary microbiome dysbiosis and LUTS severity, with specific bacterial genera such as Streptococcus and Haemophilus linked to higher International Prostate Symptom Score (IPSS) scores and PSA levels. The fecal microbiome may be associated with LUTS, although contradictory findings are reported. The review also highlights methodological inconsistencies, small sample sizes, few negative controls and a lack of comprehensive clinical data as major limitations.
CONCLUSIONS: While there is an undeniable correlation between the microbiome and LUTS/BPH, future research should aim to standardize sampling techniques and expand the score to include functional microbiome characterization, potentially leading to novel, microbiome-targeted therapeutic strategies for BPH.
In order to assess the influence of the spouse on the enhanced PCC process, the couples assigned to this group will meet together with either Dr. Lewis or the Research Audiologist for approximately 30 minutes of counseling. This counseling will be conducted with both the patient and the spouse together, giving both partners time to express their thoughts.
Single session of 15-min HD-tDCS to the right primary somatosensory cortex with an intensity of 1 mA. The session will last approximately one hour.
PURPOSE: To determine the content by am arrangement wherein no particle component exists in an absorbed and permeated hydrophilic humor where a microprobes membrane has specified pore volume and a specified or a constant quantity of the absorbed homor is subjected to a dry or wet chemical analysis. CONSTITUTION: The particle separator 1 comprises a handle part 2 and a part 3 for receiving a hydrophilic microporous membrane. The membrane comprises a separation membrane 5 and a collection membrane 7. The particle separator 1 further comprises an another small handle part 6. A central part 12 is linked with a surrounding part 9 through a weak coupling part 8 by means of the collection membrane 7. When the central part 12 abuts against a grid part 10 and an end member 16 is moved upward by the small handle part 6. the collection membrane 7 is broken along a weak coupling part 8 and the central part 12 can be separated from the surrounding part 9. The separated grid part 10 and the collection membrane 7 are subjected to a chemical analysis.
A method and apparatus for providing visual feedback to a user during personal grooming activities. A target region of the user's body at which the personal grooming operation is being carried out is tracked. Progress of the personal grooming activity of the user is monitored. At least one item of feedback relevant to the user's personal grooming activity is determined and a relevant location on the user's body for visual projection of information indicative of the item of feedback is established. The feedback information is projected onto the user's body at the relevant location, which is viewable by the user in the mirror. Because the user is focused on the personal grooming activity by looking through the mirror at the target region of the body, the feedback information will automatically be in line with the user's gaze direction and also in focus for the user's eyes. A dynamic masking function may track the user's eyes and ensure light projection is not directed to the user's eyes.
Each participant will complete a baseline (pre-dose) PET scan and a post-dose PET scan, following a 15-minute IV infusion of scopolamine. Each participant will also complete a magnetic resonance imaging (MRI) scan of the brain. The timing of the post scopolamine \[11C\] EMO PET scan tracer injection could occur 15 minutes to 48 hours after the scopolamine infusion has been completed.

In this study, the post scopolamine \[11C\] EMO PET scan tracer injection should be given 4 hours (± 5 minutes) after the scopolamine infusion of 4.0 μg/kg in up to 2 subjects. The data from those 2 subjects will be reviewed to determine the timepoint for tracer injection for the post scopolamine \[11C\] EMO PET scan in the next 2 subjects (e.g., tracer injection at 24-hour or 1-hour post-dose). If the baseline and post scopolamine PET scans are obtained on the same day, the scopolamine infusion should be started after the acquisition of the baseline PET scan has been completed. The data from the first 4 subjects will be reviewed to determine the dose level and timepoint for tracer injection in the last 2 subjects. . At least 2 hours should elapse between injections of \[11C\] EMO to allow for clearance of the tracer signal from the baseline scan and the injection of \[11C\] EMO for a post scopolamine PET scan should not be given during a scopolamine infusion. Participants will complete at least 2 visits and up to 4.
NEW MATERIAL:A tripeptide derivative (salt) expressed by the formula (A and B are arenesulfonyl, alkanesulfonyl, aroyl, acyl, etc.; X is L-, D- or DL- arginine residue). EXAMPLE:N-epsilon-(p-Tosyl)-D-lysyl-L-prolyl-L-argininal sulfate. USE:A proteolytic enzyme inhibitor. PREPARATION:For example, carboxyl group of D-lysine having protected alpha-amino group and side chain amino group is converted into an active ester and reacted with L-proline to afford protected D-lysyl-L-proline, which is then reacted with L-arginine-delta-lactam to provide a protected tripeptide-lactam. The resultant protected tripeptide-lactam is subsequently allowed to react with LiAlH4 and further reduced with hydrogen in the presence of palladium black to afford the objective tripeptide derivative expressed by the formula.
Induction therapy with 6 cycles of R-CHLIP-14 (Rituximab 375 mg/sqm, Cyclophosphamide 750 mg/sqm, Doxorubicin 50 mg/sqm, liposomal Vincristine 1,67 mg/sqm \[uncapped\], , Predniso\[lo\]ne 100mg/d d1-5) and then definitive (post-induction) restaging with FDG-PET. If FDG-PET positive 2xR plus additional radiotherapy to the initial bulky region, if FDG-PET negative only 2xR without radiotherapy. After 3xR-CHLIP-14 an interim restaging will be performed. Recruitment completed.